• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Tuesday, July 5, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Children’s Hospital Colorado first in the world to implant recently FDA-approved stent for treatment of congenital heart disease

Bioengineer by Bioengineer
May 18, 2022
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Aurora, Colo. (May 18, 2022) – Children’s Hospital Colorado (Children’s Colorado) is the first hospital in the world to implant the newly FDA-approved G-Armor Stent. Although the stent is designed to be used in the smallest of patients, it was first implanted in a Colorado father of two. The stent was developed by interventional cardiologist, Gareth Morgan, MD, who oversees the Interventional Congenital Cardiology program at  Children’s Colorado in conjunction with NuMed for Children.

Dr. Morgan and the G-Armor Stent

Credit: Children’s Hospital Colorado

Aurora, Colo. (May 18, 2022) – Children’s Hospital Colorado (Children’s Colorado) is the first hospital in the world to implant the newly FDA-approved G-Armor Stent. Although the stent is designed to be used in the smallest of patients, it was first implanted in a Colorado father of two. The stent was developed by interventional cardiologist, Gareth Morgan, MD, who oversees the Interventional Congenital Cardiology program at  Children’s Colorado in conjunction with NuMed for Children.

Unlike many other stents, the G-Armor is hand-manufactured with considerable capacity for expansion and minimal shortening during implantation. The result is a stent that can be dilated to accommodate a patient’s natural growth, potentially reducing the need for additional stent implantation – a key benefit to growing pediatric patients. The high expansion range also provides cardiac interventionalists the ability to treat a broader range of patients.

“I am proud to have led the development of the first custom stent approved by the FDA in a decade to treat congenital heart disease,” says Morgan, who is also an associate professor at the University of Colorado School of Medicine. “This new stent, in combination with our unmatched imaging technologies, removes significant surgical uncertainties, and is expected to result in improved outcomes for patients of all ages.”

The first patient was Randy Welch, who was told as a child that the small hole in his heart would close. But as a new dad working at the National Institutes of Health in Maryland, Welch learned the hole had expanded significantly and was causing his heart to pump extremely hard, which could ultimately result in heart failure. After moving back to Colorado and seeking cardiology care, Welch was quickly referred to Joseph Kay, MD, program director for the Children’s Colorado / UCHealth Adult Congenital Heart Disease program. This unique program on the Anschutz Medical Campus specializes in treating adults, like Welch, who were born with congenital heart defects.

Welch’s two options were either open heart surgery or implanting this new stent in the Children’s Colorado heart catheterization lab. With a second child on the way, Welch wanted the procedure with the lowest risk and quickest recovery time. Working with his colleague Jenny Zablah, MD, who leads the innovative interventional imaging team, Dr. Morgan created a 3D model of Welch’s heart and determined that Welch was a good candidate for the new stent.

Like many young adults with congenital heart disease, Dr. Kay and Dr. Morgan deemed that Welch’s procedure and recovery would be best managed by the congenital cardiac team at Children’s Colorado to take advantage of the hospital’s high-end imaging technologies, virtual-reality planning and the extensive experience of the entire catheterization lab team.

“Working in the medical field, I understood I needed to repair my heart, but I kept putting it off. The thought of having open-heart surgery with two babies at home wasn’t very appealing,” said Welch. “But Dr. Morgan and Dr. Kay explained how left untreated, I could go into heart failure or have a stroke. The new stent was a perfect option for me.”

Six months after surgery, Randy is feeling good, his heart looks great and his future is bright.



Share12Tweet7Share2ShareShareShare1

Related Posts

Hussein Yassine, MD

USC researcher leads effort to improve research on diet and dementia

July 4, 2022
Schematic illustration of the generation of PROTAC viruses

Researchers propose a new live-attenuated influenza A vaccine approach

July 4, 2022

UTSW researchers develop rapid COVID-19 test to identify variants in hours

July 2, 2022

Monkeypox virus on surfaces: no proof that contact can cause infection

July 1, 2022

POPULAR NEWS

  • Pacific whiting

    Oregon State University research finds evidence to suggest Pacific whiting skin has anti-aging properties that prevent wrinkles

    37 shares
    Share 15 Tweet 9
  • Telescopic contact lenses

    39 shares
    Share 16 Tweet 10
  • Emerging Omicron subvariants BA.2.12.1, BA.4 and BA.5 are inhibited less efficiently by antibodies

    37 shares
    Share 15 Tweet 9
  • The pair of Orcas deterring Great White Sharks – by ripping open their torsos for livers

    37 shares
    Share 15 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

UrbanizationVaccinesUrogenital SystemZoology/Veterinary ScienceUniversity of WashingtonViolence/CriminalsVehiclesVirologyVirusVaccineWeaponryWeather/Storms

Recent Posts

  • Fossils confirm early diversification of spiny plants in central Tibet
  • NTU Singapore and poultry firm Leong Hup Singapore collaborate to create Singapore’s first ‘zero waste’ poultry processing facility
  • Lung cancer: When radiotherapy fails
  • Link between recognizing our voice and feeling in control
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....